证券代码：301097 证券简称：天益医疗 公告编号：2025-045 宁波天益医疗器械股份有限公司 关于全资子公司为母公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、因公司经营发展需要，宁波天益医疗器械股份有限公司（以下简称"公 司"或"天益医疗"）拟与上海浦东发展银行股份有限公司宁波分行（以下简称 "浦发银行宁波分行"）签订《借款合同》，全资子公司宁波天益药业科技有限公 司（以下简称"天益药业"）拟与浦发银行宁波分行签订《最高额保证合同》，为 母公司天益医疗提供总金额人民币 1.9 亿元的连带责任保证。 2、本次担保的性质：连带责任保证。 3、本事项无需提交公司董事会及股东会审议，由相关子公司就担保事项履 行内部审批程序。 一、担保情况概述 因公司经营发展需要，天益医疗拟与浦发银行宁波分行签订《借款合同》， 全资子公司天益药业拟与浦发银行宁波分行签订《最高额保证合同》，为母公司 天益医疗提供总金额人民币 1.9 亿元的连带责任保证。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 ...

Summary of Key Points Core Viewpoint - Tianyi Medical's stock experienced a decline of 2.77% on August 28, with a trading volume of 66.35 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing and Trading Data - On August 28, Tianyi Medical had a financing purchase amount of 10.72 million yuan and a net financing purchase of 5.96 million yuan, with a total financing and securities balance of 31.14 million yuan, accounting for 3.83% of its market capitalization [1]. - The financing balance is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - There were no short sales or repayments on the same day, with the short selling balance also at zero, placing it in the 90th percentile of the past year [1]. Company Overview - Tianyi Medical, established on March 12, 1998, and listed on April 7, 2022, specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1]. - The company's revenue composition includes 59.05% from blood purification, 34.08% from ward care, and 6.87% from other sources [1]. Financial Performance - For the first half of 2025, Tianyi Medical reported a revenue of 227 million yuan, reflecting a year-on-year growth of 11.50%, while the net profit attributable to shareholders decreased by 35.23% to 9.48 million yuan [2]. - The total number of shareholders as of June 30 was 4,196, a slight decrease of 0.31%, with an average of 4,372 circulating shares per person, which increased by 0.31% [2]. Dividend and Shareholder Information - Since its A-share listing, Tianyi Medical has distributed a total of 102 million yuan in dividends, with 87.50 million yuan distributed over the past three years [3]. - As of June 30, 2025, the top ten circulating shareholders included notable funds, with some holdings remaining stable while others saw slight reductions [3].

Core Insights - Tianyi Medical (301097) reported a revenue increase but a decline in net profit for the first half of 2025, with total revenue reaching 227 million yuan, up 11.5% year-on-year, while net profit attributable to shareholders fell by 35.23% to 9.48 million yuan [1] - The company's gross margin decreased to 35.48%, down 4.42% year-on-year, and net margin dropped to 4.53%, down 30.0% [1] Financial Performance - For Q2 2025, total revenue was 129 million yuan, reflecting a year-on-year increase of 20.43, while net profit attributable to shareholders was 4.61 million yuan, a significant decline of 50.11% [1] - Total expenses (selling, administrative, and financial) amounted to 46.09 million yuan, accounting for 20.27% of revenue, which is an increase of 6.95% year-on-year [1] - Earnings per share decreased by 46.67% to 0.16 yuan, while operating cash flow per share increased by 17.8% to 0.54 yuan [1] Business Evaluation - The company's historical median Return on Invested Capital (ROIC) stands at 18.18%, but the worst year recorded a ROIC of -0.78% in 2024, indicating poor investment returns [2] - The company has experienced one loss year since its listing, necessitating further investigation into potential special circumstances [2] Debt and Cash Flow - The company maintains a healthy cash asset position, but the interest-bearing debt ratio has reached 25.75%, warranting attention to its debt situation [2] - The business model relies heavily on capital expenditures, which raises concerns about the viability and necessity of these investments [2]

Summary of Key Points Core Viewpoint - Tianyi Medical (301097.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 1.559 million shares held by seven institutions, representing 2.64% of the total share capital, down by 0.38 percentage points from the previous quarter [1]. Institutional Holdings - As of August 27, 2025, seven institutional investors disclosed their holdings in Tianyi Medical, totaling 1.559 million shares, which is 2.64% of the company's total equity [1]. - The institutional investors include notable funds such as China Merchants Bank - Penghua Hongjia Flexible Allocation Mixed Fund and China Construction Bank - Yuanxin Yongfeng聚优 Equity Fund [1]. - The total institutional holding percentage decreased by 0.38 percentage points compared to the previous quarter [1]. Public Fund Holdings - Two public funds reduced their holdings compared to the previous quarter, specifically Yuanxin Yongfeng Medical Health A and Yuanxin Yongfeng聚优 A, with a total reduction of 0.12% [1]. - One new public fund disclosed its holdings during this period, which is the Rongtong Health Industry Flexible Allocation Mixed A/B [1]. - One public fund, Penghua Quality Governance Mixed (LOF) A, was not disclosed in this quarter compared to the previous one [1].

Core Viewpoint - The company has reported its 2025 semi-annual results, highlighting key financial metrics and strategic initiatives, including share repurchase plans and stock incentive programs, while maintaining compliance with regulatory requirements [1][17][31]. Company Overview - The company, Ningbo Tianyi Medical Instruments Co., Ltd., has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4]. - The company plans to repurchase shares using its own funds, with a total repurchase amount between RMB 30 million and RMB 60 million, targeting a maximum price of RMB 50.00 per share [3][5]. Financial Data and Indicators - The company completed a share repurchase of 1,427,400 shares, representing 2.42% of its total share capital, with a total transaction amount of approximately RMB 57.64 million [5]. - The company has approved a stock incentive plan to grant 2.343 million restricted stocks to eligible employees, with a grant price of RMB 22.11 per share [6][7]. Important Events - The company has engaged in a joint investment with an affiliate to acquire CRRT business assets for EUR 43.54 million, with the transaction completed in February 2025 [9][10]. - The company is in the process of establishing an overseas production base in Thailand, reallocating funds from a previously planned project to support this initiative [11][12]. Fundraising and Usage - The company raised a total of RMB 771.77 million from its public offering, with a net amount of RMB 694.56 million after deducting fees [43]. - As of June 30, 2025, the company has nine dedicated fundraising accounts and has utilized RMB 60 million for cash management, including structured deposits and large certificates of deposit [44][45]. Compliance and Reporting - The board and supervisory committee have unanimously approved the semi-annual report and the special report on the use of raised funds, confirming compliance with relevant regulations [22][35].

Group 1 - The core point of the article is that Tianyi Medical announced the approval of multiple proposals during the 25th meeting of its third board of directors [2] Group 2 - The announcement was made on the evening of August 27 [2] - The meeting involved the review of the company's proposals [2]

Core Viewpoint - Tianyi Medical announced the approval of company-related proposals during the 21st meeting of its third supervisory board on the evening of August 27 [2] Group 1 - The company held a supervisory board meeting to discuss and approve important proposals [2]

Company Performance - Tianyi Medical reported a revenue of approximately 227 million yuan for the first half of 2025, representing a year-on-year increase of 11.5% [1] - The net profit attributable to shareholders of the listed company was approximately 9.48 million yuan, showing a year-on-year decrease of 35.23% [1] - Basic earnings per share were 0.16 yuan, reflecting a year-on-year decline of 46.67% [1] Industry Insights - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

Group 1 - The company Tianyi Medical announced the convening of its 25th meeting of the third board of directors on August 27, 2025, to review the proposal regarding the 2025 semi-annual report and its summary [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices for related listed companies [1]

Group 1 - The company reported a revenue of 227 million yuan for the first half of 2025, representing a year-on-year growth of 11.50% [1] - The net profit attributable to shareholders of the listed company was 9.48 million yuan, a year-on-year decrease of 35.23% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.04 million yuan, a year-on-year decrease of 84.63% [1] - The basic earnings per share were 0.16 yuan [1]